🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Illumina shares hold rating from Jefferies

EditorAhmed Abdulazez Abdulkadir
Published 06/03/2024, 05:52 PM
ILMN
-

On Monday, Jefferies began covering Illumina, Inc. (NASDAQ:ILMN), a leading company in next-generation sequencing technology, assigning a Hold rating to the stock with a price target of $115. The new rating reflects a cautious stance on the company's future, considering several factors that could influence its performance.

The company, while currently a dominant player in its market, faces uncertainties that affect its long-term growth prospects. These uncertainties include questions about market elasticity, growth rates, competition, operating margins, and the strategic direction under new leadership.

Jefferies' valuation takes into account the anticipated divestiture of Grail, a former subsidiary of Illumina. This transaction is expected to be finalized by the end of the second quarter of 2024, which will likely impact Illumina's business structure and financials.

The Hold rating suggests that Jefferies advises investors to maintain their current position in Illumina shares without increasing or decreasing their stake. The price target of $115 is set as the expected value of the stock in the view of the firm, based on their analysis and the current information available about the company's prospects and industry challenges.

In summary, Jefferies' coverage initiation on Illumina with a Hold rating and a $115 price target is based on a comprehensive evaluation of the company's market position and the potential hurdles it may face in the near future. The analysis considers the post-Grail divestiture scenario and the impact it may have on Illumina's operations and growth trajectory.

InvestingPro Insights

As Illumina, Inc. (NASDAQ:ILMN) navigates through a period of uncertainty and strategic shifts, real-time data from InvestingPro offers a deeper perspective on the company's financial health and market valuation. Illumina has a market capitalization of $16.61 billion, which underscores its significant presence in the next-generation sequencing technology sector. Despite a challenging past year reflected in a -49.7% one-year total return, analysts have highlighted a potential turnaround, predicting profitability this year. This optimism is tempered by a current negative P/E ratio of -12.71, indicating that the market has factored in the recent difficulties the company has faced.

InvestingPro Tips for Illumina suggest a mixed outlook: while the company is not profitable over the last twelve months, and eight analysts have revised their earnings downwards for the upcoming period, the expectation is for net income growth this year. Additionally, Illumina operates with a moderate level of debt, which could offer some financial flexibility as it adjusts its business strategy post-Grail divestiture. It's worth noting that the company does not pay a dividend, which may influence investment decisions for those seeking income-generating stocks.

For investors looking to delve further into Illumina's prospects, there are additional InvestingPro Tips available that could shed light on the company's future performance. By using the coupon code PRONEWS24, investors can receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to further insights that can guide investment decisions in a volatile market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.